NextFin News - Novo Nordisk and Eli Lilly, two pharmaceutical giants, are locked in a high-stakes battle to capture the burgeoning market for GLP-1 obesity pills as Medicare coverage for these drugs is set to begin in July 2026. Novo Nordisk announced that its Wegovy pill has surpassed 3 million prescriptions in the U.S. within five months of launch, a milestone CEO Mike Doustdar highlighted as a sign of accelerating demand despite Eli Lilly's recent entry with its Foundayo pill. Meanwhile, Lilly CEO Dave Ricks reported that Foundayo prescriptions have grown markedly since April, though he withheld specific figures.
The competition was on full display at the American Diabetes Association’s Scientific Sessions, where Novo’s Wegovy was heavily advertised alongside Lilly’s Foundayo. The upcoming Medicare coverage, which will allow seniors to access GLP-1 drugs for a $50 monthly copay instead of paying out of pocket, marks a pivotal shift in obesity treatment accessibility. Both companies are actively promoting awareness of this program but are adopting distinct marketing strategies.
Doustdar emphasized Wegovy’s broader health benefits beyond weight loss, including reductions in cardiovascular risks such as heart attacks and strokes. He argued that these advantages should make Wegovy the preferred choice for seniors, stating, "With the Wegovy high dose, why would you not take a product that has the same efficacy, percentage wise, than my competitor? On top of it, you get kidney, liver, heart, stroke protection, let’s say free of charge." Doustdar’s comments reflect his role as CEO since mid-2025, tasked with revitalizing Novo’s sales and pipeline after a period of internal upheaval. His optimistic stance on Wegovy’s competitive edge is consistent with his broader strategy to diversify Novo’s cardiometabolic portfolio.
Conversely, Lilly’s Ricks pitched convenience as Foundayo’s key advantage, highlighting its ease of use—taken with food and other medications at any time of day—compared to Wegovy’s more restrictive dosing requirements. Ricks, who has led Lilly through a period of aggressive expansion in obesity treatments, expressed confidence in Medicare’s rollout and the involvement of insurers like Humana. He framed the Medicare pilot as a potential catalyst to reclassify obesity care as standard health care, emphasizing the need to demonstrate cost-effectiveness through ongoing studies.
Ricks’ perspective is informed by Lilly’s internal data showing sustained patient adherence and usage rates below 20% among beneficiaries, a figure that contrasts with broader payer reluctance. For instance, Cigna recently ceased coverage of GLP-1 obesity drugs for its employees, citing concerns over the large eligible population and patients discontinuing treatment after weight loss goals are met. This payer hesitancy underscores a significant risk to the market’s growth trajectory.
Both companies are advancing next-generation obesity drugs. Lilly presented promising Phase 3 data for retatrutide, a triple agonist that achieved an average 28% body weight reduction, rivaling bariatric surgery outcomes. Ricks indicated plans to offer retatrutide through LillyDirect, a direct-to-consumer platform, reflecting a strategic push to broaden access. Novo’s pipeline includes CagriSema, combining Wegovy’s active ingredient with cagrilintide, though investor enthusiasm has been muted due to efficacy comparisons favoring Lilly’s candidates. Doustdar remains committed to CagriSema’s launch, viewing it as integral to Novo’s future.
This analysis primarily draws on statements from Doustdar and Ricks at the American Diabetes Association meeting and their recent interviews with CNBC. Both executives have vested interests in promoting their respective products and strategies, and their views do not necessarily represent a consensus among healthcare payers or independent analysts. The market’s evolution will depend heavily on Medicare’s implementation success, patient adherence patterns, and broader insurer willingness to cover these costly therapies.
While the Medicare coverage expansion is poised to increase access dramatically, uncertainties remain around long-term cost-effectiveness and real-world outcomes. The contrasting approaches of Novo and Lilly—emphasizing clinical benefits versus convenience—highlight the nuanced challenges in winning patient and payer acceptance. The next several quarters will be critical in determining which company can sustain momentum and translate early prescription gains into durable market leadership.
Explore more exclusive insights at nextfin.ai.
